◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › 0-9 › 2196

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-11

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Shanghai, China with about 40,603 employees. Its market capitalization is roughly CNY 46 billion. In the fiscal year ended 2025-12-31, 2196 reported CNY 41.7B in revenue and CNY 3.4B in net income.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others.

Interactive charts & full statements →

2196 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 41.7B	CNY 41.1B	CNY 41.4B	CNY 44.0B
Gross Profit	CNY 20.9B	CNY 19.7B	CNY 19.8B	CNY 20.8B
Operating Income (EBIT)	CNY 3.1B	CNY 3.2B	CNY 1.6B	CNY 3.6B
Net Income	CNY 3.4B	CNY 2.8B	CNY 2.4B	CNY 3.7B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2196 Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	CNY 10.1B	CNY 12.3B	CNY 10.1B	CNY 9.4B	CNY 10.2B
Gross Profit	CNY 5.0B	CNY 6.7B	CNY 4.9B	CNY 4.5B	CNY 4.7B
Operating Income (EBIT)	CNY 819M	CNY 1.0B	CNY 763M	CNY 658M	CNY 541M
Net Income	CNY 871M	CNY 847M	CNY 937M	CNY 765M	CNY 759M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2196 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Dividends Paid	(CNY 1.9B)	(CNY 2.1B)	(CNY 2.5B)	(CNY 2.4B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2196 Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Dividends Paid	(CNY 242M)	(CNY 236M)	(CNY 296M)	(CNY 302M)	(CNY 360M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2196 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 120.1B	CNY 117.5B	CNY 113.5B	CNY 107.2B	—
Total Liabilities	CNY 58.2B	CNY 57.5B	CNY 56.9B	CNY 53.1B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2196 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4559 · Zeria Pharmaceutical Co., Ltd. — $91 billion
4569 · KYORIN Pharmaceutical Co., Ltd. — $64 billion
4886 · ASKA Pharmaceutical Holdings Co.,Ltd. — $58 billion
4554 · Fuji Pharma Co., Ltd. — $48 billion
GALD · GALDERMA GROUP N — $40 billion
4577 · Daito Pharmaceutical Co.,Ltd. — $37 billion
4595 · Mizuho Medy Co.,Ltd. — $33 billion
9273 · Koa Shoji Holdings Co.,Ltd. — $32 billion

← 2195 All “0-9” companies 2197 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.